Hepatitis B vaccine- Yisheng Biopharma

Drug Profile

Hepatitis B vaccine- Yisheng Biopharma

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yisheng Biopharma
  • Class
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 21 Nov 2016 Phase-I clinical trials in Hepatitis B in Singapore before November 2016 (Parenteral)
  • 21 Nov 2016 Yisheng Biopharma completes a phase I trial in Hepatitis B in Singapore
  • 21 Nov 2016 Yisheng Biopharma plans a phase II trial for Hepatitis B in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top